| http://www.w3.org/ns/prov#value | - ical trials were just emerging from the discovery pipe-line and, in some cases, there was a dearth of preclinical and human mechanistic data to IMMUNOLOGYTen Years of the Immune Tolerance Network: An Integrated Clinical Research OrganizationJeff rey A. Bluestone,1,2* Alan M. Krensky,1,3 Laurence A. Turka,1,4 Daniel Rotrosen,5 Jeff rey B. Matthews1 Published 17 February 2010; Volume 2 Issue 19 19cm
|
